Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 4

recruiting
3 972
countries
28
conditions
2 103

677 trials match your criteria

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Plasma cell myeloma refractory

Recruiting

Phase II Study of Teclistamab Plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma After 1–3 Prior Therapies

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide

Acute myeloid leukaemia

Recruiting

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine

Epstein-Barr virus infection

Recruiting

Safety and Tolerability of Tenofovir Alafenamide Dose Escalation in Healthy Adults for Epstein‑Barr Virus Infection

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tenofovir Alafenamide

Colorectal cancer metastatic

Recruiting

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Systemic lupus erythematosus

Recruiting

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab

Plasma cell myeloma refractory

Recruiting

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Non-small cell lung cancer+1

Recruiting

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.